Global cervical cancer market to grow up to $4.1 billion by 2016

Published on January 21, 2010 at 7:10 AM · No Comments

Research and Markets ( has announced the addition of GlobalData's new report "Cervical Cancer - Pipeline Analysis and Market Forecasts to 2016" to their offering.

“Cervical Cancer - Pipeline Analysis and Market Forecasts to 2016”

Cervical Cancer - Pipeline Analysis and Market Forecasts to 2016 GlobalData, the industry analysis specialist's new report, "Cervical Cancer - Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global cervical cancer market. The report identifies the key trends shaping and driving the market, and provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global cervical cancer sector.

The Cervical Cancer Market is Forecast to Show Significant Growth until 2016

GlobalData has estimated the global cervical cancer market to be valued at $1.8 billion in 2009. It is expected to grow to $4.1 billion by 2016, at a Compound Annual Growth Rate (CAGR) of 11.9% between 2009 and 2016. This growth is primarily attributed to increased competition among the existing cervical cancer vaccines in the market. The vaccines will be primarily responsible for the growth of the market with the predicted increase in their uptake and sales. The success of these vaccines has driven a lot of companies into research activity.

Competition in Cervical Cancer Market Becoming More Intense

GlobalData analyzed that the current competition in the cervical cancer market is becoming more intense due to increased competition between two cervical cancer vaccines. Both the vaccines, Gardasil and Cervarix, are trying to overtake the market share of each other. Merck's Gardasil, which has been in the market for a long time, is facing competition from GSK's Cervarix which was approved in 2009 in the US. There is competition between them to expand the label indications, to provide broader coverage against the HPV strains, for inclusion in national immunization schedules around the world. These two vaccines form the major cervical cancer market activity and the drugs have a very limited role in the activity of the current market. These vaccines will be responsible for major future market growth also.

Strategic Competitor Assessment of the Vaccines in Cervical Cancer Market

Source: GlobalData

Note: This figure doesnt include drugs, as there is only one FDA approved drug for late stage cervical cancer and some common chemotherapy agents that are used widely for most types of cancer


Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | हिन्दी | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment